NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
07:11
Saudi authorities confirm 12 dead and more than 300 injured after the attack on Riyadh Airport
23:02
Ukraine’s first reaction after Donald Trump called for President Volodymyr Zelenskyy to be replaced: “There are two leaders in the world calling for Ukraine to have a new president: the first is President Trump, and the second is dictator Putin”
22:34
Volodymyr Zelenskyy, after the Trump–Putin agreement: “Russia expressed its gratitude for the lifting of sanctions on diesel fuel exports by launching five glide bombs at residential buildings in Zaporizhzhia”
22:03
Donald Trump states that it is time for Ukraine “to have a new leader who can reach an agreement” with Russia
21:43
Inter Milan return to the top of Serie A after a clear victory over Parma
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
